Evidence map›Paper›PMID 35796530›Full record

ArticleCancer2022

Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma.

Neehar D Parikh, Neil Mehta, Maarouf A Hoteit, Ju Dong Yang, Binu V John, Andrew M Moon, Reena J Salgia, Anjana Pillai, Ihab Kassab, Naba Saeed and 15 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 10 institutions in 1 country.

Neehar D ParikhDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-5874-9933
Neil MehtaDivision of Gastroenterology, University of California, San Francisco, San Francisco, California, USA.
Maarouf A HoteitDivision of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ju Dong YangDivision of Gastroenterology, Cedars Sinai, Los Angeles, California, USA.ORCID 0000-0001-7834-9825
Binu V JohnDivision of Gastroenterology, University of Miami, Miami, Florida, USA.ORCID 0000-0002-2002-9682
Andrew M MoonDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.
Reena J SalgiaDivision of Gastroenterology, Henry Ford Health System, Detroit, Michigan, USA.
Anjana PillaiDivision of Gastroenterology, University of Chicago, Chicago, Illinois, USA.
Ihab KassabDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Naba SaeedDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
Emil ThyssenDivision of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, Texas, USA.ORCID 0000-0002-3579-0431
Piyush NathaniDivision of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, Texas, USA.
Jeffrey McKinneyDivision of Gastroenterology, University of California, San Francisco, San Francisco, California, USA.
Wesley ChanDivision of Gastroenterology, University of California, San Francisco, San Francisco, California, USA.
Claire DurkinDivision of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Matthew ConnorDivision of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-1186-0623
Manaf AlsudaneyDivision of Gastroenterology, Cedars Sinai, Los Angeles, California, USA.
Rajesh KonjetiDivision of Gastroenterology and Hepatology, University of Kentucky, Lexington, Kentucky, USA.
Brenda DurandComprehensive Transplant Center, Cedars Sinai, Los Angeles, California, USA.
Nicholas N NissenComprehensive Transplant Center, Cedars Sinai, Los Angeles, California, USA.
Hannah P KimDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA.
Raghavendra PaknikarDivision of Gastroenterology, University of Chicago, Chicago, Illinois, USA.
Nicole E RichDivision of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, Texas, USA.ORCID 0000-0003-2740-8818
Matthew J SchipperDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Amit G SingalDivision of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, Texas, USA.ORCID 0000-0002-1172-3971
Cedars-Sinai Medical Center · USThe University of Texas Southwestern Medical Center · USUniversity of Michigan · USHospital of the University of Pennsylvania · USUniversity of California, San Francisco · USUniversity of Chicago · USUniversity of North Carolina at Chapel Hill · USHenry Ford Health System · USUniversity of Kentucky · USUniversity of Miami · US

Funding

Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinomaR01MD012565 · NIMHD · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT, YOPP, ADAM · 2018 to 2022
$4.3M
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United StatesU01CA230694 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SINGAL, AMIT · 2018 to 2022
$3.5M
NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTIONU01CA230669 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOK, ANNA S.F., SU, GRACE L. · 2018 to 2022
$3.3M
NCI NIH HHS U01 CA230669NCI NIH HHS U01 CA230694NIMHD NIH HHS R01 MD012565
6 · The paper itself

Abstract

backgroundSustained viral response (SVR) improves survival for patients with hepatitis C (HCV) and hepatocellular carcinoma (HCC) after curative treatment; however, the benefit of SVR in those with active HCC with a significant competing risk of mortality is unknown. This study aimed to evaluate the association between SVR and outcomes in patients with active HCC.

methodsThe authors performed a multicenter, retrospective cohort study including consecutive adults with HCV cirrhosis and treatment-naive HCC diagnosed between 2014 and 2018. Patients were stratified into two groups: active viremia (n = 431) and SVR before HCC diagnosis (n = 135). All patients underwent nonsurgical therapy as their initial treatment and were followed until liver transplantation, last follow-up, or death. The primary outcome was incident or worsening hepatic decompensation within 6 months and the secondary outcome was overall survival. All analyses used inverse probability of treatment weights (IPTW) to account for differences between the nonrandomized cohorts.

resultsPost-SVR patients had significantly lower odds of hepatic decompensation compared to viremic patients (odds ratio [OR], 0.18; 95% confidence interval [CI], 0.06-0.59). Results were consistent among subgroups of patients with Child Pugh A cirrhosis (OR, 0.22; 95% CI, 0.04-0.77), Barcelona Clinic Liver Cancer stage B/C HCC (OR, 0.20; 95% CI, 0.04-0.65), and those receiving nonablative HCC therapies (OR, 0.21; 95% CI, 0.07-0.67). However, in IPTW multivariable Cox regression, SVR was not associated with improved survival (hazard ratio, 0.79; 95% CI, 0.56-1.12).

conclusionsPatients with HCV-related HCC and SVR are less likely to experience hepatic decompensation than viremic patients, suggesting patients with HCC who are undergoing nonsurgical therapies may benefit from DAA treatment.

Indexed as

Carcinoma, HepatocellularHepatitis CHepatitis C, ChronicLiver NeoplasmsAdultAntiviral AgentsHepacivirusHumansLiver CirrhosisRetrospective StudiesAntiviral AgentsDAAdecompensationHCCHCVSVR

Identifiers

PMID35796530
PMCPMC9545187
OpenAlexW4284889874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.